Next Diagnostic Step: Metabolic Screening with Fasting Glucose and Lipid Panel
In this 11-year-old obese child with confirmed hypertension and acanthosis nigricans, the next step is to obtain fasting glucose, fasting insulin, and a lipid profile to screen for insulin resistance syndrome—not to pursue testing for rare secondary causes of hypertension. 1
Rationale: Obesity-Related Hypertension vs. Secondary Causes
Why Metabolic Screening Takes Priority
The American Heart Association explicitly recommends fasting plasma glucose testing for children who are overweight and have signs of insulin resistance such as acanthosis nigricans and hypertension. 1
Acanthosis nigricans is a cutaneous marker of insulin resistance and specifically warrants screening for insulin resistance and type 2 diabetes in obese children, not evaluation for rare endocrine causes of hypertension. 1
The clinical picture—obesity (>95th percentile), acanthosis nigricans, positive family history of type 2 diabetes and hypertension—strongly suggests primary (essential) hypertension related to insulin resistance syndrome, not a secondary endocrine or renovascular cause. 1
Initial Laboratory Panel Should Include
- Fasting plasma glucose (primary screening test) 1
- Fasting insulin with HOMA-IR calculation (provides better assessment of insulin resistance than glucose alone) 1
- Lipid profile (dyslipidemia is part of insulin resistance syndrome) 1
- Basic metabolic panel and urinalysis (to screen for renal parenchymal disease) 1
When NOT to Test for Secondary Causes
The AAP Guidelines Are Clear
Testing for rare secondary causes such as primary hyperaldosteronism (aldosterone-renin ratio) or pheochromocytoma (catecholamines) is NOT indicated in obese children with acanthosis nigricans and a family history of metabolic disease. 1
Secondary-Cause Workup Is Reserved For:
- Stage 2 hypertension (≥95th percentile + 12 mmHg) 1
- Clinical findings suggesting a specific secondary etiology (e.g., abdominal bruit for renovascular disease, cushingoid features for Cushing syndrome) 1
- Abnormal screening labs (hypokalemia, elevated creatinine, abnormal urinalysis) 1
- Lack of response to lifestyle modification and initial therapy 1
- Age <6 years, where secondary causes predominate 1
This patient meets none of these criteria—he has Stage 1 hypertension in the context of obesity and metabolic syndrome markers.
Why Each Option Is Inappropriate
Aldosterone-Renin Ratio
- Not indicated in obese children with metabolic syndrome features unless hypokalemia is present or there is treatment-resistant hypertension. 1
- Primary hyperaldosteronism is exceedingly rare in this clinical context.
Catecholamine Levels
- Not indicated without symptoms of pheochromocytoma (episodic headaches, palpitations, sweating, pallor). 1
- The patient is asymptomatic except for elevated blood pressure.
Renal Artery Ultrasound
- Not indicated in obese children ≥6 years with a positive family history of metabolic disease and no findings suggesting renovascular disease (no abdominal bruit, no history of umbilical artery catheterization). 1
- Renovascular disease is rare in this age group without specific risk factors.
Cortisol Level
- The American Heart Association advises that cortisol measurement to screen for Cushing syndrome is not warranted in obese children unless characteristic signs such as striae, moon facies, buffalo hump, or growth deceleration are present. 1
- This patient has acanthosis nigricans (a marker of insulin resistance), not cushingoid features.
Confirming the Diagnosis of Hypertension
Before Extensive Laboratory Workup
The AAP recommends ambulatory blood pressure monitoring (ABPM) to confirm the diagnosis of hypertension before pursuing extensive evaluation. 2, 1
ABPM should be performed for children with office BP measurements in the elevated BP category for 1 year or more, or with Stage 1 hypertension over 3 clinic visits. 2
This step helps rule out white coat hypertension, which affects up to half of children evaluated for elevated office BP. 2
Clinical Significance of Acanthosis Nigricans
Strong Association with Metabolic Risk
Research demonstrates a strong relationship between acanthosis nigricans and metabolic syndrome in obese children (p=0.003). 3
Children with acanthosis nigricans have significantly higher fasting insulin, HOMA-IR, triglycerides, systolic blood pressure, and lower HDL cholesterol compared to obese children without acanthosis nigricans. 4, 5
The prevalence ratio for type 2 diabetes in patients with acanthosis nigricans is 1.97 after controlling for age and BMI, suggesting it may be an independent risk factor. 6
Management After Metabolic Screening
First-Line Therapy
Lifestyle modification (dietary changes and increased physical activity) is the first-line therapy for insulin resistance syndrome in obese children. 1
Blood pressure target is <90th percentile for age, sex, and height. 1
When to Consider Pharmacotherapy
If target blood pressure is not achieved after 3–6 months of lifestyle intervention, pharmacologic treatment with an ACE inhibitor or ARB should be considered. 1
Pharmacological therapy for hypertension is indicated if BP remains persistently above the 95th percentile despite lifestyle modification, especially if there is evidence of target organ changes (left ventricular hypertrophy, microalbuminuria, retinal vascular abnormalities). 2
Common Pitfalls to Avoid
Do not pursue expensive and invasive testing for rare secondary causes in obese children with clear metabolic syndrome features—this leads to unnecessary cost, patient discomfort, and delayed appropriate management. 1
Do not overlook the need for ABPM confirmation before labeling a child as hypertensive and initiating extensive workup. 2
Do not fail to screen for insulin resistance when acanthosis nigricans is present—this is a critical opportunity for early intervention to prevent progression to type 2 diabetes. 1, 6